Investment Rating - The report maintains a "Buy" rating for the company [3] Core Insights - The company achieved a revenue of 1.379 billion RMB in 2025, representing a year-on-year growth of 40.63%. The net profit attributable to shareholders was 173 million RMB, with a remarkable growth of 416.37% [9] - The growth in revenue is primarily driven by the robust performance of the model animals and preclinical CRO services, with model animal revenue reaching 622 million RMB, up 59.86% year-on-year, and preclinical CRO service revenue increasing by 75.24% to 352 million RMB [9] - The company is expected to continue its strong growth trajectory, with projected revenues of 1.847 billion RMB in 2026, 2.416 billion RMB in 2027, and 3.144 billion RMB in 2028, corresponding to growth rates of 34.0%, 30.8%, and 30.1% respectively [2] Financial Performance Summary - In 2025, the company reported a net profit of 173 million RMB, with a significant increase in R&D expenses to 438 million RMB, reflecting a 35.23% year-on-year growth [9] - The earnings per share (EPS) for 2025 was 0.39 RMB, with projections of 0.76 RMB in 2026, 1.19 RMB in 2027, and 1.68 RMB in 2028 [2] - The price-to-earnings (P/E) ratio is projected to decrease from 133 in 2025 to 31 by 2028, indicating an improving valuation as earnings grow [2] Business Growth Drivers - The company is enhancing its global leadership in innovative animal models, with plans to expand production capacity significantly by the end of 2026 [9] - The preclinical CRO business is expanding its service offerings and global network, with plans to enhance infrastructure in Boston in 2026 [9] - The antibody development platform is expected to leverage AI and automation, with over 350 collaboration agreements signed, and several projects entering clinical trials [9]